Moving towards efficient therapies in type 1 diabetes: To combine or not to combine?
- 30 April 2007
- journal article
- review article
- Published by Elsevier BV in Autoimmunity Reviews
- Vol. 6 (5), 315-322
- https://doi.org/10.1016/j.autrev.2006.09.013
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing TregsJCI Insight, 2006
- Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic miceNature Immunology, 2005
- Lost in translationThe Journal of Experimental Medicine, 2005
- Pancreatic β-Cell Function and Immune Responses to Insulin After Administration of Intranasal Insulin to Humans At Risk for Type 1 DiabetesDiabetes Care, 2004
- In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune DiabetesThe Journal of Experimental Medicine, 2004
- Intranasally administered insulin intended for prevention of type 1 diabetes—a safety study in healthy adultsDiabetes/Metabolism Research and Reviews, 2003
- T cells respond to heat shock protein 60 via TLR2: activation of adhesion and inhibition of chemokine receptorsThe FASEB Journal, 2003
- The DPT‐1 trial: a negative result with lessons for future type 1 diabetes preventionDiabetes/Metabolism Research and Reviews, 2002
- Promotion of -Cell Regeneration by Betacellulin in Ninety Percent-Pancreatectomized RatsEndocrinology, 2001
- β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trialThe Lancet, 2001